Natixis Advisors LLC Raises Position in Edwards Lifesciences Corporation $EW

Natixis Advisors LLC lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 257,302 shares of the medical research company’s stock after acquiring an additional 20,574 shares during the period. Natixis Advisors LLC’s holdings in Edwards Lifesciences were worth $20,010,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in shares of Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after purchasing an additional 10,078 shares during the period. Atlantic Union Bankshares Corp grew its holdings in Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after purchasing an additional 11,384 shares in the last quarter. OMERS ADMINISTRATION Corp grew its holdings in Edwards Lifesciences by 97.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after purchasing an additional 21,950 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after buying an additional 1,423,365 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW opened at $85.08 on Thursday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The company has a market capitalization of $49.42 billion, a PE ratio of 46.49, a PEG ratio of 2.24 and a beta of 0.93. The company’s 50 day moving average price is $82.49 and its 200 day moving average price is $81.55.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the prior year, the firm earned $0.59 earnings per share. The company’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on EW. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, February 11th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. UBS Group reiterated a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Finally, Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,897,284.92. This represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,371,239.08. This trade represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 74,123 shares of company stock worth $6,275,599 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Brokerage consensus remains constructive — Edwards has an average rating of “Moderate Buy,” which supports longer-term investor demand and suggests analysts see upside vs. current valuation. Article Title
• Positive Sentiment: Equity research and trade ideas continue to include EW among attractive medical-instruments names, citing product pipeline, secular TAVR/TMV growth and margin upside — a positive for investor interest and potential inflows. Article Title
• Neutral Sentiment: Management presented at recent healthcare conferences (Barclays and Leerink); transcripts are available for investors to assess guidance, R&D and commercial cadence but contained no market-moving surprises in summary. These presentations can influence sentiment depending on Q&A details. Barclays Transcript Leerink Transcript
• Negative Sentiment: Significant insider selling by senior finance staff: CFO Scott Ullem sold 13,000 shares (a ~24.7% reduction in his holding) at ~$84.92 — a sizeable, public reduction by the company’s finance chief can alarm investors about near-term conviction. SEC Filing
• Negative Sentiment: Additional insider sale: VP Daniel Lippis sold 1,019 shares at ~$85.38. Though smaller, combined insider selling activity increases pressure on sentiment. SEC Filing
• Negative Sentiment: Short interest jumped sharply in February (up ~56.6% to ~12.38M shares, ~2.1% of shares outstanding), suggesting increased bearish bets that can amplify downward moves and volatility on negative headlines. (No link provided)

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.